KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Current Investments (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Cash & Current Investments data on record, last reported at $2.2 billion in Q3 2025.

  • For Q3 2025, Cash & Current Investments fell 9.79% year-over-year to $2.2 billion; the TTM value through Sep 2025 reached $2.2 billion, down 9.79%, while the annual FY2024 figure was $2.3 billion, 1.44% down from the prior year.
  • Cash & Current Investments reached $2.2 billion in Q3 2025 per IONS's latest filing, down from $2.3 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.5 billion in Q3 2024 and bottomed at $1.8 billion in Q1 2021.
  • Average Cash & Current Investments over 5 years is $2.2 billion, with a median of $2.1 billion recorded in 2025.
  • Peak YoY movement for Cash & Current Investments: fell 23.66% in 2021, then rose 17.98% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $2.1 billion in 2021, then decreased by 6.06% to $2.0 billion in 2022, then grew by 17.33% to $2.3 billion in 2023, then dropped by 1.44% to $2.3 billion in 2024, then fell by 2.5% to $2.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $2.2 billion in Q3 2025, $2.3 billion in Q2 2025, and $2.1 billion in Q1 2025.